trending Market Intelligence /marketintelligence/en/news-insights/trending/tu0vp7nqbt-m_tnmi80tvq2 content esgSubNav
In This List

Astellas names chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Astellas names chief medical officer

Astellas Pharma Inc. promoted Bernhardt Zeiher to the position of chief medical officer, effective April 1.

Zeiher will continue serving as president of development while also overseeing all other functions of Astellas' medical and development organization, including clinical and research quality assurance, medical affairs, pharmacovigilance, planning and administration and regulatory affairs.

Zeiher, who began his career at Astellas in 2010 as vice president and therapeutic area leader, was previously promoted to president of development in 2015.

Tokyo-based Astellas Pharma is a pharmaceutical company, which manufactures, markets, and imports/exports pharmaceutical products worldwide.